-
Something wrong with this record ?
Altered cytochrome P450 activities and expression levels in the liver and intestines of the monosodium glutamate-induced mouse model of human obesity
V. Tomankova, B. Liskova, L. Skalova, H. Bartikova, I. Bousova, L. Jourova, P. Anzenbacher, J. Ulrichova, E. Anzenbacherova,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Sodium Glutamate * MeSH
- Insulin blood metabolism MeSH
- Liver enzymology metabolism MeSH
- Blood Glucose metabolism MeSH
- Leptin blood metabolism MeSH
- Humans MeSH
- Lipids blood MeSH
- RNA, Messenger analysis genetics MeSH
- Lipid Metabolism MeSH
- Mice MeSH
- Obesity blood chemically induced genetics metabolism MeSH
- Eating MeSH
- Intestines enzymology metabolism MeSH
- Cytochrome P-450 Enzyme System analysis genetics metabolism MeSH
- Up-Regulation MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
UNLABELLED: Cytochromes P450 (CYPs) are enzymes present from bacteria to man involved in metabolism of endogenous and exogenous compounds incl. drugs. Our objective was to assess whether obesity leads to changes in activities and expression of CYPs in the mouse liver, small intestine and colon. MAIN METHODS: An obese mouse model with repeated injection of monosodium glutamate (MSG) to newborns was used. Controls were treated with saline. All mice were sacrificed at 8 months. In the liver and intestines, levels of CYP mRNA and proteins were analyzed using RT-PCR and Western blotting. Activities of CYP enzymes were measured with specific substrates of human orthologous forms. KEY FINDINGS: At the end of the experiment, body weight, plasma insulin and leptin levels as well as the specific content of hepatic CYP enzymes were increased in obese mice. Among CYP enzymes, hepatic CYP2A5 activity, protein and mRNA expression increased most significantly in obese animals. Higher activities and protein levels of hepatic CYP2E1 and 3A in the obese mice were also found. No or a weak effect on CYPs 2C and 2D was observed. In the small intestine and colon, no changes of CYP enzymes were detected except for increased expression of CYP2E1 and decreased expression of CYP3A mRNAs in the colon of the obese mice. SIGNIFICANCE: Results of our study suggest that the specific content and activities of some liver CYP enzymes (especially CYP2A5) can be increased in obese mice. Higher activity of CYP2A5 (CYP2A6 human ortholog) could lead to altered metabolism of drug substrates of this enzyme (valproic acid, nicotine, methoxyflurane).
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031345
- 003
- CZ-PrNML
- 005
- 20180525110149.0
- 007
- ta
- 008
- 151005s2015 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.lfs.2015.04.014 $2 doi
- 035 __
- $a (PubMed)25998026
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Tománková, Veronika $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. $7 xx0224707
- 245 10
- $a Altered cytochrome P450 activities and expression levels in the liver and intestines of the monosodium glutamate-induced mouse model of human obesity / $c V. Tomankova, B. Liskova, L. Skalova, H. Bartikova, I. Bousova, L. Jourova, P. Anzenbacher, J. Ulrichova, E. Anzenbacherova,
- 520 9_
- $a UNLABELLED: Cytochromes P450 (CYPs) are enzymes present from bacteria to man involved in metabolism of endogenous and exogenous compounds incl. drugs. Our objective was to assess whether obesity leads to changes in activities and expression of CYPs in the mouse liver, small intestine and colon. MAIN METHODS: An obese mouse model with repeated injection of monosodium glutamate (MSG) to newborns was used. Controls were treated with saline. All mice were sacrificed at 8 months. In the liver and intestines, levels of CYP mRNA and proteins were analyzed using RT-PCR and Western blotting. Activities of CYP enzymes were measured with specific substrates of human orthologous forms. KEY FINDINGS: At the end of the experiment, body weight, plasma insulin and leptin levels as well as the specific content of hepatic CYP enzymes were increased in obese mice. Among CYP enzymes, hepatic CYP2A5 activity, protein and mRNA expression increased most significantly in obese animals. Higher activities and protein levels of hepatic CYP2E1 and 3A in the obese mice were also found. No or a weak effect on CYPs 2C and 2D was observed. In the small intestine and colon, no changes of CYP enzymes were detected except for increased expression of CYP2E1 and decreased expression of CYP3A mRNAs in the colon of the obese mice. SIGNIFICANCE: Results of our study suggest that the specific content and activities of some liver CYP enzymes (especially CYP2A5) can be increased in obese mice. Higher activity of CYP2A5 (CYP2A6 human ortholog) could lead to altered metabolism of drug substrates of this enzyme (valproic acid, nicotine, methoxyflurane).
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a krevní glukóza $x metabolismus $7 D001786
- 650 _2
- $a systém (enzymů) cytochromů P-450 $x analýza $x genetika $x metabolismus $7 D003577
- 650 _2
- $a přijímání potravy $7 D004435
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inzulin $x krev $x metabolismus $7 D007328
- 650 _2
- $a střeva $x enzymologie $x metabolismus $7 D007422
- 650 _2
- $a leptin $x krev $x metabolismus $7 D020738
- 650 _2
- $a metabolismus lipidů $7 D050356
- 650 _2
- $a lipidy $x krev $7 D008055
- 650 _2
- $a játra $x enzymologie $x metabolismus $7 D008099
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a obezita $x krev $x chemicky indukované $x genetika $x metabolismus $7 D009765
- 650 _2
- $a messenger RNA $x analýza $x genetika $7 D012333
- 650 12
- $a glutamát sodný $7 D012970
- 650 _2
- $a upregulace $7 D015854
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Liskova, Barbora $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Skalova, Lenka $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic.
- 700 1_
- $a Bartikova, Hana $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic.
- 700 1_
- $a Bousova, Iva $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic.
- 700 1_
- $a Jourova, Lenka $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Anzenbacher, Pavel $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. $7 xx0034447
- 700 1_
- $a Ulrichova, Jitka $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Anzenbacherová, Eva $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Electronic address: eva.anzenbacherova@upol.cz. $7 stk2008428613
- 773 0_
- $w MED00003147 $t Life sciences $x 1879-0631 $g Roč. 133, č. - (2015), s. 15-20
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25998026 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20180525110337 $b ABA008
- 999 __
- $a ok $b bmc $g 1092221 $s 914471
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 133 $c - $d 15-20 $e 20150518 $i 1879-0631 $m Life sciences $n Life Sci $x MED00003147
- LZP __
- $a Pubmed-20151005